Lupin Ltd logo

Lupin Ltd

NSE: LUPIN BSE: 500257

₹1928.90

+6.90 (0.36%)

Wed, 28 Oct 2026, 03:44 pm

mtf coin illustrationMTF 5xInvest in Lupin Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)88028.32
PE Ratio15.98
Dividend0.94
Health TechnologyHealth Technology
Pharmaceuticals: OtherPharmaceuticals: Other
24.5K24.5K

Lupin Share Price Live Chart

1 Day

+6.90 (0.36%)

No Result Found

Summary

  • Market Cap (in Cr)

    89585.99

  • Net Profit (in Cr)

    5355.47

  • P/B

    4.71

  • Sector P/E

    36.16

  • P/E

    19.83

  • EV/EBITDA

    12.29

  • Debt/Equity (Industry)

    0.19

  • Interest Cover (Industry)

    13.14

  • ROCE (Industry)

    12.29

  • RONW (Industry)

    10.69

  • ROE

    27.01

  • ROCE

    27.44

  • Debt/Equity

    0.30

  • EPS (TTM)

    130.25

  • Dividend Yield

    0.92

  • Book Value

    490.90

  • Interest Cover

    16.82

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends after 3 years are expected to be well covered by earnings (6.1x coverage).
  • Lupin's earnings are expected to grow significantly at over 20% yearly.
  • Lupin's earnings growth is expected to exceed the India market average.
  • Lupin's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • The company is paying a dividend however it is incurring a loss.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Lupin's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Lupin's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Lupin is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersSEPT 2026JUN 2026MAR 2026DEC 2025SEPT 2025
Promoters46.8446.8546.8646.8946.90
FII23.2822.4221.7121.4920.49
DII23.7824.6525.3225.5826.55
Public6.096.086.116.036.06
Government0.000.000.000.010.01

Read More

Technical Analysis

RSI

44.32

MACD

-38.46

50 DMA

2072.16

200 DMA

2245.03

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2408.872245.672137.932082.471974.731919.271756.07
Fibonacci2245.672183.322144.812082.472020.121981.611919.27
Camarilla2075.082060.122045.162082.472015.242000.281985.32

Pivots Level: Classic

R3

+326.40

2408.87

R2

+163.20

2245.67

R1

+55.47

2137.93

2082.47
2082.47
Pivot Point
LTP: 1972.70

S1

-107.73

1974.73

S2

-163.20

1919.27

S3

-326.40

1756.07

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1958.82

  • 20-EMA

    1982.79

  • 30-EMA

    2013.24

  • 50-EMA

    2070.55

  • 100-EMA

    2152.21

  • 200-EMA

    2179.05

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
08 Jul 2026agm
07 May 2026dividend₹18.00 Dividend /Share17 Jul 2026
07 May 2026board-meetingsAccounts, Quarterly Results, Dividend
12 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
14 Jul 2025agm
25 Jun 2025dividendFinal Dividend - Rs. - 1225 Jul 2025
14 May 2025dividend₹12.00 Dividend /Share25 Jul 2025
09 Jul 2024agm
16 Jun 2024dividendFinal Dividend - Rs. - 816 Jul 2024

Read More

Peer Comparison

Lupin Ltd logo

Lupin Ltd

Laurus Labs Ltd logo

Laurus Labs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Read More

Lupin Ltd About

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1983

Headquarters

CEO

M D Gupta

Employees

Contact

Website icon

Website

https://www.lupin.com/

Email icon

Email

investorservices@lupinpharma.com

Phone icon

Phone

91-22-6640 2323

Location icon

Location

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Read More

Lupin Ltd Company History

YearHistory
2020
  • Lupin's Pithampur facilities pass MHRA inspection.
  • Lupin launches generic arthritis relief tablet in the US.
  • Lupin receives EIR from US FDA for Florida inhalation research centre.
  • Lupin receives EIR from US FDA for Nagpur plant.
  • Lupin receives US FDA approval for generic product.
2021
  • Lupin receives US FDA approval for generic anti-fungal cream.
  • LupinLife launches ayurvedic energy supplement Be One.
  • Lupin launches Posaconazole delayed-release tablets.
  • Lupin launches generic Wilson's disease drug in the US.
  • Lupin launches generic diarrhea drug in the US.
2022
  • Lupin receives US FDA approval for Efinaconazole Topical Solution.
  • Lupin launches first reference laboratory in Kolkata.
  • Lupin receives US FDA approval for Vigabatrin for Oral Solution USP.
  • Lupin completes acquisition of brands from Anglo-French.
  • Lupin launches Merzee Capsules in the US.
2023
  • Lupin launches Softovac Liqui fibre liquid fibre product.
  • Lupin launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the US.
  • Lupin launches Rocuronium Bromide Injection in the US.
  • Lupin launches Diazepam Rectal Gel in the US.
  • Lupin agrees to acquire 5 drug brands from Menarini for Rs 101 crore.
2024
  • Lupin and Slurrp conclude Lupin Aptivate Achchi Bhookh Quiz.
  • Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio.
  • Lupin receives US FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets.
  • Lupin acquires 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio.
  • Lupin's Pune R&D facility awarded LEED Platinum Certification.
  • Lupin launches Bumetanide Injection USP in the United States.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy81892197713 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell81892197713 Oct 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockSell528611894.714 Jul 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockBuy528611894.714 Jul 2025
BNP PARIBAS ARBITRAGEblockSell7479561449.225 Jan 2024
SOCIETE GENERALEblockBuy7479561449.225 Jan 2024
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell22847774714 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy22847774714 Nov 2022

Read More

Lupin Ltd News

Lupin appoints Brian Savage as Chief Legal Officer

Lupin Ltd has appointed Brian Savage as President and Chief Legal Officer effective October 22, 2026. Savage brings extensive global pharma legal experience from Teva.

22 Oct 2026

companies

Lupin ESG rating dips to 70 in FY26

Lupin Limited's NSE Sustainability ESG rating fell to 70 in FY26 from 71 in FY25. The decline stems from a one-point drop in both Social and Governance scores.

15 Oct 2026

companies

Lupin gets US FDA nod for Phytonadione injectable

Lupin received US FDA approval for Phytonadione Injectable Emulsion 1 MG/0.5 ML Pre-filled Syringe, marking a regulatory clearance for its injectable product portfolio in the US market.

08 Oct 2026

companies

Lupin launches world's first triple-combo COPD drug in India

Lupin Limited launched Formoflo-G MDI, the world's first fixed-dose triple combination inhaler for COPD, approved by DCGI. The drug targets over 55 million patients in India.

06 Oct 2026

companies

Lupin subsidiary completes buyback, becomes wholly owned

Lupin Ltd announced that its step-down subsidiary Multicare Pharmaceuticals Philippines has completed a share buyback, becoming a wholly owned entity.

01 Oct 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Lupin Ltd?

    As of 28/10/2026 at 9:14 PM, Lupin Ltd shares are trading at ₹1928.90.

  • 2.What is the market cap. of Lupin Ltd?

    As of 28/10/2026, the market capitalization of Lupin Ltd is ₹88,028.32 crore.

  • 3.When was Lupin Ltd founded?

    Lupin Ltd was founded in 1983.

  • 4.What are the P/E and P/B ratios of Lupin Ltd?

    As of 28/10/2026, Lupin Ltd has a P/E ratio of 15.98 and a P/B ratio of 4.71.

  • 5.How can I buy shares of Lupin Ltd?

    You can buy shares of Lupin Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Lupin Ltd?

    As of September,2026, promoters hold 46.84% in Lupin Ltd, while FIIs, DIIs and public shareholders hold 23.28%, 23.78% and 6.09%, respectively. The government holds 0.00%.

  • 7.Does Lupin Ltd pay dividends?

    Yes, Lupin Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹18.00 Dividend /Share per share.

  • 8.What is the dividend yield of Lupin Ltd?

    As of 28 October, 2026, the dividend yield of Lupin Ltd stands at 0.94%.

  • 9.What are the latest financial results of Lupin Ltd?

    For the financial year ended March 2025, Lupin Ltd reported revenue of ₹22,228.00 crore and a net profit of ₹3,282.00 crore.

  • 10.What is the Stock symbol of Lupin Ltd?

    LUPIN is the stock symbol of Lupin Ltd.

  • 11.Who is the CEO of Lupin Ltd?

    The CEO of Lupin Ltd is M D Gupta.

pocketful logo lightpocketful logo dark
PricingBecome a Partner
search icon
/

No results for ''

Popular search

  • popular search iconSuzlon Energy Ltd
  • popular search iconIndian Railway Finance Corporation Ltd
  • popular search iconTata Motors Ltd
  • popular search iconTata Steel Ltd
  • popular search iconRail Vikas Nigam Ltd

Recent search

      Log In
      search icon

      No results for ‘’

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd
        • popular search iconReliance Industries Ltd
        pocketful logo lightpocketful logo dark
        • Pricing
        • Become a Partner
        Log In
        • home icon
        • arrow iconstocks
        • arrow iconlupin ltd
        • Overview
        • Analysis
        • Financials
        • Ratios
        • shareholding
        • Technical Analysis
        • Corporate Actions
        • Peer Comparison
        • About
        • Company History
        • Deals
        • News
        • FAQs

        Open Your Free Demat Account Now!

        Step into a world of zero fees and limitless opportunities!

        pocketful logo

        • Quick Links

          • Open Demat Account
          • Pocketful Web
          • Pocketful App
          • Pricing
          • Authorised Person
          • Pocketful Calculators
          • Compliance Links

        • Pages

          • Tools
          • Blogs
          • ETF Screener
          • IPO
          • ETF
          • Bonds
          • Index Heat Map

        • Products

          • Stocks
          • Commodity
          • Subscription
          • Free Stock Screener
          • Pocketful GPT
          • MTF
          • Mutual Funds

        • Company

          • About us
          • Contact us
          • Terms and Conditions
          • Policies & Procedures
          • Privacy Policy
          • Disclosure
          • Careers

        • Socials

          • Facebook iconFacebook
          • Twitter iconTwitter
          • Instagram iconInstagram
          • LinkedIn iconLinkedIn
          • Youtube iconYoutube

        2022-25 Pocketful. All rights reserved, Built with in India

        Version -5.76

        app image 1app image 2

        Stocks:

        AllABCDEFGHIJKLMNOPQRSTUVWXYZ

        Explore

        Calculators
        Popular Calculators
        Group Stocks
        Asset Management Companies
        Popular Stocks
        Indian Indices
        Sector Wise Stocks
        IPO
        Share Market
        Best MF Schemes
        Platforms
        Resources
        Gold Rates in Top Cities
        Silver Rates in Top Cities

        Others:

        NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

        Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800